April 11, 2018
A Pennsylvania federal judge on Tuesday transferred to Connecticut two proposed investor class actions against Teva Pharmaceutical Industries Ltd. claiming the company hid the negative fallout from its $40.5 billion acquisition of Actavis Generics, ruling that the cases were substantially similar to other class actions already consolidated there.
August 30, 2017
A proposed class of investors in Teva Pharmaceutical Industries Ltd. slapped the drugmaker and several of its current and former executives with a suit in Pennsylvania federal court on Wednesday accusing them of concealing the negative fallout from Teva’s $40.5 billion acquisition of Actavis Generics.